查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1539203

肌萎縮側索硬化症 (ALS) 市場：全球規模、佔有率、趨勢分析、機會、預測，2019-2030 年

Amyotrophic Lateral Sclerosis Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019-2030, Segmented By Type; By Treatment; By End User; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球肌萎縮側索硬化症 (ALS) 市場預計將以複合年成長率大幅擴張，到 2030 年將超過 14.5 億美元。

全球肌萎縮側索硬化症 (ALS) 市場的推動因素包括 ALS 患病率的上升、認知的提高、治療方法方案的進步以及更有效治療方法，得益於政府的資助，該市場正在蓬勃發展。

領先的策略諮詢和市場研究公司 BlueWeave Consulting 在最近的一項研究中估計，2023 年全球肌萎縮側索硬化症 (ALS) 市場以金額為準將達到 9.02 億美元。 BlueWeave 預測，在 2024 年至 2030 年的預測期內，全球肌萎縮側索硬化症 (ALS) 市場規模將以 7.10% 的複合年成長率成長，到 2030 年將達到 14.56 億美元。全球肌萎縮側索硬化症 (ALS) 市場的促進因素包括盛行率的增加、醫學研究的進步以及對 ALS 認知的提高。診斷技術的改進和治療 ALS 的生物技術投資的增加是主要原因。此外，政府對罕見疾病研究的支持和舉措，以及製藥公司和研究機構之間的合作，也支持了市場的成長。治療 ALS 的新治療方法的開發和臨床試驗數量的增加進一步推動了全球肌萎縮側索硬化症 (ALS) 市場的成長。

機會 - 新治療方法研究和發展計劃

肌萎縮側索硬化症（ALS）全球市場的成長主要是由旨在發現新治療方法的不斷增加的研發舉措所推動的。製藥公司和研究機構大力投資研發，開發基因療法、幹細胞療法和候選藥物等創新療法。這些治療方法進展預計將改善患者預後，提供更有效的治療選擇，推動市場成長，並為改善 ALS 管理帶來希望。

地緣政治緊張局勢加劇對肌萎縮側索硬化症（ALS）全球市場的影響

地緣政治緊張局勢的加劇可能會對全球肌萎縮側索硬化症（ALS）市場產生重大影響。國際貿易和供應鏈的中斷可能會導致 ALS 治療藥物的生產和分配延遲。加強監管和貿易限制可能會影響基本藥物和醫療設備的供應。此外，ALS 研究的資金可能會被轉用於解決眼前的地緣政治問題，從而減緩治療方法進展。外匯波動和經濟不穩定可能會增加醫療保健提供者和患者的成本。總體而言，地緣政治不穩定可能會阻礙獲得有效的 ALS 治療和市場開發，從而影響患者護理和市場成長。

ALS藥物的主要最終使用者是專科醫院。

全球肌萎縮側索硬化症（ALS）市場的最終用戶是專業設施以及研究和學術機構。專業醫療機構為全球肌萎縮側索硬化症 (ALS) 市場最終用戶的成長做出了重大貢獻。這是因為 ALS 患者可以獲得專門的治療和先進的治療方案。這些設施提供診斷、多學科治療和臨床試驗等綜合服務，使其成為患者的首選，並賦予他們在市場上的競爭優勢。

競爭格局

全球肌萎縮側索硬化症 (ALS) 市場競爭激烈，眾多公司都在爭奪更大的市場佔有率。市場的主要企業包括三菱田邊製藥、大塚製藥、BrainStorm Therapeutics、Biogen Inc.、Corestem、AB Science、F. Hoffmann-La Roche AG、Biohaven Pharmaceutical、Sun Pharmaceutical 和 Ionis Pharmaceuticals, Inc.。這些公司正在增加對研發活動、併購、合資、聯盟、授權合約的投資，並推出新產品和服務，以進一步鞏固其在全球肌萎縮側索硬化症（ALS）市場的地位。

該報告的詳細分析提供了有關全球肌萎縮側索硬化症（ALS）市場的成長潛力、未來趨勢和統計數據的資訊。它還重點關注推動市場總規模預測的因素。該報告致力於提供全球肌萎縮側索硬化症 (ALS) 市場的最新技術趨勢以及產業見解，以幫助決策者做出明智的策略決策。此外，我們也分析了市場的成長動力、挑戰和競爭力。

目錄

第1章 研究框架

第 2 章執行摘要

第3章全球肌萎縮側索硬化症 (ALS) 市場洞察

  • 產業價值鏈分析
  • DROC分析
    • 生長促進因子
      • 世界各地 ALS 發病率不斷增加
      • ALS 治療的醫學研究和技術進展
      • 醫療保健支出和不斷提高的醫療意識
      • 易患神經系統疾病的老年人口增加
    • 抑制因素
      • ALS 治療方案高成本
      • 目前的治療方法效果有限
      • 藥品核准嚴格監理要求
    • 機會
      • 新治療方法的研究和開發工作
      • 製藥公司與研究機構的合作
      • 用於早期檢測的診斷工具的技術進步
    • 任務
      • 對實驗性 ALS 治療的倫理擔憂
      • 不同地區獲得 ALS 治療的機會不平等
  • 科技進步/最新趨勢
  • 法律規範
  • 波特五力分析

第4章全球肌萎縮側索硬化症（ALS）市場：行銷策略

第5章全球肌萎縮側索硬化症（ALS）市場：價格分析

第6章全球肌萎縮側索硬化症 (ALS) 市場：區域分析

第7章全球肌萎縮側索硬化症（ALS）市場概述

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
      • 散發性肌萎縮側索硬化症 (SALS)
      • 遺傳性肌萎縮側索硬化症 (FALS)
    • 透過治療
      • 藥品
      • 物理治療
      • 呼吸治療
      • 語言治療
      • 其他
    • 按最終用戶
      • 專業中心
      • 研究/學術機構
      • 其他
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲（中東/非洲）

第8章 北美肌萎縮側索硬化症（ALS）市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 透過治療
    • 按最終用戶
    • 按國家/地區
      • 美國
      • 加拿大

第9章歐洲肌萎縮側索硬化症（ALS）市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 透過治療
    • 按最終用戶
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第10章亞太地區肌萎縮側索硬化症（ALS）市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 透過治療
    • 按最終用戶
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 亞太地區其他國家

第11章拉丁美洲肌萎縮側索硬化症（ALS）市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 透過治療
    • 按最終用戶
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲

第12章中東和非洲肌萎縮側索硬化症（ALS）市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 透過治療
    • 按最終用戶
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 中東和非洲其他地區

第13章競爭格局

  • 主要企業及其產品列表
  • 2023年全球肌萎縮側索硬化症（ALS）市場佔有率分析
  • 透過管理參數進行競爭基準化分析
  • 重大策略發展（合併、收購、聯盟等）

第14章地緣政治緊張局勢加劇對全球肌萎縮側索硬化症（ALS）市場的影響

第15章 公司簡介（公司簡介、財務矩陣、競爭格局、關鍵人員、主要競爭對手、聯絡方式、策略展望、SWOT分析）

  • Mitsubishi Tanabe Pharma Corporation
  • Otsuka Pharmaceutical Co., Ltd
  • BrainStorm Therapeutics
  • Biogen Inc.
  • Corestem
  • AB Science
  • F.Hoffmann-La Roche AG
  • Biohaven Pharmaceutical
  • Sun Pharmaceutical
  • Ionis Pharmaceuticals, Inc.
  • 其他主要企業

第16章 主要策略建議

第17章調查方法

簡介目錄
Product Code: BWC24582

Global Amayotrophic Lateral Sclerosis (ALS) Market Size to Expand at Significant CAGR to Surpass USD 1.45 Billion by 2030

Global Amayotrophic Lateral Sclerosis (ALS) Market is thriving due to rising ALS prevalence, increased awareness, advancements in therapeutic options, and government funding in enhancing research and development efforts for more effective treatments.

BlueWeave Consulting, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Amayotrophic Lateral Sclerosis (ALS) Market size by value at USD 902 million in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Amayotrophic Lateral Sclerosis (ALS) Market size to expand at a CAGR of 7.10% reaching a value of USD 1,456 million in 2030. Global Amyotrophic Lateral Sclerosis (ALS) Market is driven by increasing incidence rates, advancements in medical research, and rising awareness about ALS. Enhanced diagnostic techniques and growing investment in biotechnology for ALS treatment contribute significantly. Additionally, governments' support and initiatives for rare disease research, along with collaborations between pharmaceutical companies and research institutions, propel market growth. The development of novel therapies and increasing clinical trials for ALS treatments further boost the growth of Global Amayotrophic Lateral Sclerosis (ALS) Market.

Opportunity - R&D initiatives for novel therapies

The growth of Global Amyotrophic Lateral Sclerosis (ALS) Market is significantly driven by increased research and development initiatives aimed at discovering novel therapies. Pharmaceutical companies and research institutions are investing heavily in R&D to develop innovative treatments, such as gene therapies, stem cell therapies, and novel drug candidates. These advancements are expected to improve patient outcomes and provide more effective treatment options, fueling market growth and offering hope for better management of ALS.

Impact of Escalating Geopolitical Tensions on Global Amayotrophic Lateral Sclerosis (ALS) Market

Escalating geopolitical tensions can significantly impact the Global Amyotrophic Lateral Sclerosis (ALS) Market. Disruptions in international trade and supply chains may lead to delays in the production and distribution of ALS medications and therapies. Increased regulatory scrutiny and trade restrictions can affect the availability of essential drugs and medical devices. Additionally, funding for ALS research may be diverted to address immediate geopolitical concerns, slowing advancements in treatment options. Fluctuations in currency exchange rates and economic instability can increase costs for healthcare providers and patients. Overall, geopolitical instability can hinder the accessibility and development of effective ALS treatments, impacting patient care and market growth.

Specialty Centers Are Major End Users of ALS Therapies

Global Amyotrophic Lateral Sclerosis (ALS) Market is comprised of specialty centers and research & academic institutes as end users. The specialty centers segment is a higher contributor to the growth of Global Amyotrophic Lateral Sclerosis (ALS) Market by end user. The segment dominates due to the specialized care and advanced treatment options provided by these centers, which cater specifically to ALS patients. These facilities offer comprehensive services, including diagnostics, multidisciplinary care, and access to clinical trials, making them the preferred choice for patients and driving their prominence in the market.

Competitive Landscape

Global Amayotrophic Lateral Sclerosis (ALS) Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd, BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Amayotrophic Lateral Sclerosis (ALS) Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Amayotrophic Lateral Sclerosis (ALS) Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technology trends in Global Amayotrophic Lateral Sclerosis (ALS) Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Amyotrophic Lateral Sclerosis (ALS) Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing prevalence of ALS globally
      • 3.2.1.2. Advances in medical research and technology for ALS treatment
      • 3.2.1.3. Growing healthcare expenditure and awareness
      • 3.2.1.4. Rising geriatric population susceptible to neurological disorders
    • 3.2.2. Restraints
      • 3.2.2.1. High cost of ALS treatment options
      • 3.2.2.2. Limited effectiveness of current therapies
      • 3.2.2.3. Stringent regulatory requirements for drug approval
    • 3.2.3. Opportunities
      • 3.2.3.1. Research and development initiatives for novel therapies
      • 3.2.3.2. Collaborations between pharmaceutical companies and research institutions
      • 3.2.3.3. Technological advancements in diagnostic tools for early detection
    • 3.2.4. Challenges
      • 3.2.4.1. Ethical concerns related to experimental ALS therapies
      • 3.2.4.2. Uneven access to ALS treatments across different regions
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Amyotrophic Lateral Sclerosis (ALS) Market: Marketing Strategies

5. Global Amyotrophic Lateral Sclerosis (ALS) Market: Pricing Analysis

6. Global Amyotrophic Lateral Sclerosis (ALS) Market: Geographical Analysis

7. Global Amyotrophic Lateral Sclerosis (ALS) Market Overview

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share and Forecast
    • 7.2.1. By Type
      • 7.2.1.1. Sporadic ALS (SALS)
      • 7.2.1.2. Familial ALS (FALS)
    • 7.2.2. By Treatment
      • 7.2.2.1. Medication
      • 7.2.2.2. Physical Therapy
      • 7.2.2.3. Respiratory Therapy
      • 7.2.2.4. Speech Therapy
      • 7.2.2.5. Others
    • 7.2.3. By End User
      • 7.2.3.1. Specialty Centers
      • 7.2.3.2. Research & Academic Institutes
      • 7.2.3.3. Others
    • 7.2.4. By Region
      • 7.2.4.1. North America
      • 7.2.4.2. Europe
      • 7.2.4.3. Asia Pacific (APAC)
      • 7.2.4.4. Latin America (LATAM)
      • 7.2.4.5. Middle East and Africa (MEA)

8. North America Amyotrophic Lateral Sclerosis (ALS) Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.1.1. By Type
      • 8.2.4.1.2. By Treatment
      • 8.2.4.1.3. By End User
      • 8.2.4.2. Canada
      • 8.2.4.2.1. By Type
      • 8.2.4.2.2. By Treatment
      • 8.2.4.2.3. By End User

9. Europe Amyotrophic Lateral Sclerosis (ALS) Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. Germany
      • 9.2.4.1.1. By Type
      • 9.2.4.1.2. By Treatment
      • 9.2.4.1.3. By End User
      • 9.2.4.2. United Kingdom
      • 9.2.4.2.1. By Type
      • 9.2.4.2.2. By Treatment
      • 9.2.4.2.3. By End User
      • 9.2.4.3. Italy
      • 9.2.4.3.1. By Type
      • 9.2.4.3.2. By Treatment
      • 9.2.4.3.3. By End User
      • 9.2.4.4. France
      • 9.2.4.4.1. By Type
      • 9.2.4.4.2. By Treatment
      • 9.2.4.4.3. By End User
      • 9.2.4.5. Spain
      • 9.2.4.5.1. By Type
      • 9.2.4.5.2. By Treatment
      • 9.2.4.5.3. By End User
      • 9.2.4.6. Belgium
      • 9.2.4.6.1. By Type
      • 9.2.4.6.2. By Treatment
      • 9.2.4.6.3. By End User
      • 9.2.4.7. Russia
      • 9.2.4.7.1. By Type
      • 9.2.4.7.2. By Treatment
      • 9.2.4.7.3. By End User
      • 9.2.4.8. The Netherlands
      • 9.2.4.8.1. By Type
      • 9.2.4.8.2. By Treatment
      • 9.2.4.8.3. By End User
      • 9.2.4.9. Rest of Europe
      • 9.2.4.9.1. By Type
      • 9.2.4.9.2. By Treatment
      • 9.2.4.9.3. By End User

10. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Treatment
    • 10.2.3. By End User
    • 10.2.4. By Country
      • 10.2.4.1. China
      • 10.2.4.1.1. By Type
      • 10.2.4.1.2. By Treatment
      • 10.2.4.1.3. By End User
      • 10.2.4.2. India
      • 10.2.4.2.1. By Type
      • 10.2.4.2.2. By Treatment
      • 10.2.4.2.3. By End User
      • 10.2.4.3. Japan
      • 10.2.4.3.1. By Type
      • 10.2.4.3.2. By Treatment
      • 10.2.4.3.3. By End User
      • 10.2.4.4. South Korea
      • 10.2.4.4.1. By Type
      • 10.2.4.4.2. By Treatment
      • 10.2.4.4.3. By End User
      • 10.2.4.5. Australia & New Zealand
      • 10.2.4.5.1. By Type
      • 10.2.4.5.2. By Treatment
      • 10.2.4.5.3. By End User
      • 10.2.4.6. Indonesia
      • 10.2.4.6.1. By Type
      • 10.2.4.6.2. By Treatment
      • 10.2.4.6.3. By End User
      • 10.2.4.7. Malaysia
      • 10.2.4.7.1. By Type
      • 10.2.4.7.2. By Treatment
      • 10.2.4.7.3. By End User
      • 10.2.4.8. Singapore
      • 10.2.4.8.1. By Type
      • 10.2.4.8.2. By Treatment
      • 10.2.4.8.3. By End User
      • 10.2.4.9. Vietnam
      • 10.2.4.9.1. By Type
      • 10.2.4.9.2. By Treatment
      • 10.2.4.9.3. By End User
      • 10.2.4.10. Rest of APAC
      • 10.2.4.10.1. By Type
      • 10.2.4.10.2. By Treatment
      • 10.2.4.10.3. By End User

11. Latin America Amyotrophic Lateral Sclerosis (ALS) Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Treatment
    • 11.2.3. By End User
    • 11.2.4. By Country
      • 11.2.4.1. Brazil
      • 11.2.4.1.1. By Type
      • 11.2.4.1.2. By Treatment
      • 11.2.4.1.3. By End User
      • 11.2.4.2. Mexico
      • 11.2.4.2.1. By Type
      • 11.2.4.2.2. By Treatment
      • 11.2.4.2.3. By End User
      • 11.2.4.3. Argentina
      • 11.2.4.3.1. By Type
      • 11.2.4.3.2. By Treatment
      • 11.2.4.3.3. By End User
      • 11.2.4.4. Peru
      • 11.2.4.4.1. By Type
      • 11.2.4.4.2. By Treatment
      • 11.2.4.4.3. By End User
      • 11.2.4.5. Rest of LATAM
      • 11.2.4.5.1. By Type
      • 11.2.4.5.2. By Treatment
      • 11.2.4.5.3. By End User

12. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Market

  • 12.1. Market Size & Forecast, 2019-2030
    • 12.1.1. By Value (USD Billion)
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By Treatment
    • 12.2.3. By End User
    • 12.2.4. By Country
      • 12.2.4.1. Saudi Arabia
      • 12.2.4.1.1. By Type
      • 12.2.4.1.2. By Treatment
      • 12.2.4.1.3. By End User
      • 12.2.4.2. UAE
      • 12.2.4.2.1. By Type
      • 12.2.4.2.2. By Treatment
      • 12.2.4.2.3. By End User
      • 12.2.4.3. Qatar
      • 12.2.4.3.1. By Type
      • 12.2.4.3.2. By Treatment
      • 12.2.4.3.3. By End User
      • 12.2.4.4. Kuwait
      • 12.2.4.4.1. By Type
      • 12.2.4.4.2. By Treatment
      • 12.2.4.4.3. By End User
      • 12.2.4.5. South Africa
      • 12.2.4.5.1. By Type
      • 12.2.4.5.2. By Treatment
      • 12.2.4.5.3. By End User
      • 12.2.4.6. Nigeria
      • 12.2.4.6.1. By Type
      • 12.2.4.6.2. By Treatment
      • 12.2.4.6.3. By End User
      • 12.2.4.7. Algeria
      • 12.2.4.7.1. By Type
      • 12.2.4.7.2. By Treatment
      • 12.2.4.7.3. By End User
      • 12.2.4.8. Rest of MEA
      • 12.2.4.8.1. By Type
      • 12.2.4.8.2. By Treatment
      • 12.2.4.8.3. By End User

13. Competitive Landscape

  • 13.1. List of Key Players and Their Offerings
  • 13.2. Global Amyotrophic Lateral Sclerosis (ALS) Market Share Analysis, 2023
  • 13.3. Competitive Benchmarking, By Operating Parameters
  • 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Impact of Escalating Geopolitical Tensions on Global Amyotrophic Lateral Sclerosis (ALS) Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 15.1. Mitsubishi Tanabe Pharma Corporation
  • 15.2. Otsuka Pharmaceutical Co., Ltd
  • 15.3. BrainStorm Therapeutics
  • 15.4. Biogen Inc.
  • 15.5. Corestem
  • 15.6. AB Science
  • 15.7. F.Hoffmann-La Roche AG
  • 15.8. Biohaven Pharmaceutical
  • 15.9. Sun Pharmaceutical
  • 15.10. Ionis Pharmaceuticals, Inc.
  • 15.11. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

  • 17.1. Qualitative Research
    • 17.1.1. Primary & Secondary Research
  • 17.2. Quantitative Research
  • 17.3. Market Breakdown & Data Triangulation
    • 17.3.1. Secondary Research
    • 17.3.2. Primary Research
  • 17.4. Breakdown of Primary Research Respondents, By Region
  • 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable